Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib with Carboplatin/Paclitaxel in Advanced Ovarian Cancer
NCT04807166Phase 2Active, not recruiting
- Start
- Aug 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC). Primary endpoint: Progression Free Survival. Started Aug 2021; status: active, not recruiting.
02
Drugs
anlotinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT04807166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04807166.